Jefferies Downgrades Orexigen Therapeutics (OREX) to Hold, Value Limited Just Beyond Cash After Contrave Failure
Tweet Send to a Friend
Jefferies downgraded Orexigen Therapeutics (NASDAQ: OREX) from Buy to Hold and slashes its price target from $17 to $2.50 after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
